Messoud Ashina - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Messoud Ashina's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Messoud Ashina
Verified
Professor, University of Copenhagen and Associate Editor, Brain
Beats
Lifestyle and Environment Development Business ArtsTopical issues
Topics that don't fall in the lifestyle and wellness wheelhouse
Content
By Messoud Ashina| The New England Journal of Medicine Verified AbstractTargeting pituitary adenylate cyclase–activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear. In a phase 2, double-blind, randomized, placebo-controlled trial, we enrolled adult participants (18 to 65 years of age) with migraine for whom two to four previous preventive treatments had failed to provide a benefit.
By Messoud Ashina| LinkedIn@ Results from the nationwide headache in Denmark (HINDER) panel: inadequate delivery of headache care in DK that provides free and universal coverage for all its residents. Read about the implications👇
By Messoud Ashina| The New England Journal of Medicine Verified AbstractTargeting pituitary adenylate cyclase–activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear. In a phase 2, double-blind, randomized, placebo-controlled trial, we enrolled adult participants (18 to 65 years of age) with migraine for whom two to four previous preventive treatments had failed to provide a benefit.
Company Info
Brain
Hillerod, Denmark
+45 38 66 50 00